Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 554,314 |
|
|||||
| News | - | ||||||
| Day High | 34.38 | Low High |
|||||
| Day Low | 34.08 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Inhibrx Inc | INBX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.085 | -0.25% | 34.105 | 13:35:22 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 34.21 | 34.08 | 34.38 | 34.19 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,776 | 554,314 | US$ 34.11 | US$ 18,909,806 | - | 14.305 - 39.79 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 13:36:37 | 1 | US$ 34.105 | USD |
Inhibrx Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.62B | 47.39M | - | 1.8M | -241.36M | -5.09 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Inhibrx News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/22/2024 | 08:54 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 5/20/2024 | 20:48 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 5/17/2024 | 16:29 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/17/2024 | 15:25 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 5/10/2024 | 17:36 | PR Newswire (US) | Inhibrx, Inc. Announces Updated When-Issued Trading Date for.. |
| 5/09/2024 | 15:08 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/08/2024 | 15:57 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/08/2024 | 15:42 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/08/2024 | 15:37 | PR Newswire (US) | Inhibrx, Inc. Announces Record Date and Expected.. |
| 5/06/2024 | 16:16 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 3/11/2024 | 15:26 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 3/08/2024 | 15:08 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INBX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 34.60 | 34.73 | 34.08 | 34.42 | 669,922 | -0.495 | -1.43% |
| 1 Month | 34.16 | 34.75 | 33.725 | 34.35 | 588,593 | -0.055 | -0.16% |
| 3 Months | 36.63 | 37.10 | 33.725 | 34.80 | 538,497 | -2.53 | -6.89% |
| 6 Months | 20.69 | 39.79 | 19.585 | 34.60 | 627,359 | 13.42 | 64.84% |
| 1 Year | 22.91 | 39.79 | 14.305 | 29.04 | 515,481 | 11.20 | 48.87% |
| 3 Years | 16.84 | 47.90 | 7.67 | 26.17 | 430,001 | 17.27 | 102.52% |
| 5 Years | 19.70 | 50.97 | 7.67 | 26.18 | 366,666 | 14.41 | 73.12% |
Inhibrx Description
| Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency. |
